Dexcom Inc. insider Michael Jon Brown reported a sale of company common stock on July 15, 2026. According to the Form 4 filed July 16, Brown sold 1,700 shares of Dexcom common stock at a price of $74.42 per share. The transaction was reported as a sale of common stock and generated gross proceeds of approximately $126,514 before any taxes, fees, or commissions. The filing states that the shares were sold under a Rule 10b5-1 trading plan that Brown adopted on November 26, 2025. Such plans allow insiders to set up prearranged trading instructions at a time when they are not in possession of material nonpublic information, providing a structured way to sell shares over time. The explanatory note says the plan “allows the orderly disposition of shares owned by Mr. Brown” and that the shares reported in this filing were sold pursuant to that plan. The report also provides detail on Brown’s remaining equity interests, noting that the reported holdings include 74,753 unvested restricted stock units. Those RSUs consist of 39,019 units granted on March 8, 2026, vesting through March 8, 2029; 19,948 units granted on March 8, 2025, vesting through March 8, 2028; 8,549 units granted on March 8, 2025, vesting through March 8, 2027; and 7,237 units granted on March 8, 2024, vesting through March 8, 2027. The filing was signed on Brown’s behalf by Jereme M. Sylvain as attorney-in-fact on July 16, 2026. The document does not clearly state Brown’s total beneficial ownership after the sale in the provided text, beyond the disclosure that his holdings include the 74,753 unvested RSUs.